PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Borbath, I.; Cohn, A. L.; Goyal, L.; Lamarca, A.; Macarulla, T.; Oh, D. Y.; Roychowdhury, S.; Sadeghi, S.; Shroff, R. T.; Howland, M.; Li, A.; Cho, T.; Pande, A.; Javle, M. |
| Abstract Title: | PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S701 |
| End Page: | S702 |
| Language: | English |
| ACCESSION: | WOS:000573469101302 |
| DOI: | 10.1016/j.annonc.2020.08.1130 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1014TiP -- Source: Wos |
